Hospital Pharmacy - April 2020 - 111

Lorenzo et al
5. Girard TD, Jackson JC, Pandharipande PP, et al. Delirium as
a predictor of long-term cognitive impairment in survivors of
critical illness. Crit Care Med. 2010;38:1513-1520.
6. Devlin JW, Roberts RJ, Fong JJ, et al. Efficacy and safety of
quetiapine in critically ill patients with delirium: a prospective,
multicenter, randomized, double-blind, placebo-controlled
pilot study. Crit Care Med. 2010;38:419-427.
7. Yoon H, Park K, Choi W, et al. Efficacy and safety of haloperidol versus atypical antipsychotic medications in the treatment
of delirium. BMC Psychiatry. 2013;13:240.
8. Sipahimalani A, Masand PS. Olanzapine in the treatment of
delirium. Psychosomatics. 1998;39:422-430.
9. Skrobik YK, Bergeron N, Dumont M, Gottfried SB. Olanzapine
vs haloperidol: treating delirium in a critical care setting.
Intensive Care Med. 2004;30:444-449.
10. Kim S, Yoo J, Lee S, et al. Risperidone versus olanzapine for the treatment of delirium. Hum Psychopharmacol.
2010;25:298-302.
11. Zyprexa (olanzapine). [Prescribing information]. Indianapolis,
IN: Lilly USA LLC; December 2014.
12. Zyprexa Relprevv (olanzapine). [Prescribing information].
Indianapolis, IN: Eli Lilly and Co; September 2015.
13. Chan EW, Taylor DM, Knott JC, Phillips GA, Castle DJ, Kong
DC. Intravenous droperidol or olanzapine as an adjunct to
midazolam for the acutely agitated patient: a multicenter, randomized, double-blind, placebo-controlled clinical trial. Ann
Emerg Med. 2013;61:72-81.
14. Chan EW, Knott JC, Taylor DM, Phillips GA, Kong DC.
Intravenous olanzapine-another option for the acutely agitated patient? Emerg Med Australas. 2009;21:241-242.

111
15. Martel ML, Klein LR, Rivard RL, Cole JB. A large retrospective cohort of patients receiving intravenous olanzapine
in the emergency department. Acad Emerg Med. 2016;23:
29-35.
16. Chan EW, Knott JC, Taylor DM, Kong DCM. Intravenous
olanzapine for acute agitation in the emergency department. J
Pharm Pract. 2011;41:135-137.
17. Bergeron N, Dubois MJ, Dumont M, Dial S, Skrobik Y.
Intensive Care Delirium Screening Checklist: evaluation
of a new screening tool. Intensive Care Med. 2001;27:859864.
18. Sessler CN, Grap MJ, Brophy GM. Multidisciplinary management of sedation and analgesia in critical care. Semin Resp Crit
Care Med. 2001;22:211-226.
19. Kongsamut S, Kang J, Chen XL, Roehr J, Rampe D. A comparison of the receptor binding and HERG channel affinities
for a series of antipsychotic drugs. Eur J Pharmacol. 2002;450:
37-41.
20. Lehmann FD, Eggleston DW, Wang D. Validation and clinical utility of the hERG IC50:Cmax ratio to determine the
risk of drug induced torsades de pointes: a meta-analysis.
Pharmacotherapy. 2018;38(3):341-348.
21. Marder SR, Sorsaburu S, Dunayevich E, et al. Case reports
of postmarketing adverse event experiences with olanzapine intramuscular treatment in patients with agitation. J Clin
Psychiatry. 2010;71(4):433-441.
22. Devlin JW, Skrobik Y, Gelinas C, et al. Clinical practice guidelines for the prevention and management of pain, agitation/
sedation, delirium, immobility, and sleep disruption in adult
patients in the ICU. Crit Care Med. 2018;46:e825-e173.

Hospital Pharmacy - April 2020

Table of Contents for the Digital Edition of Hospital Pharmacy - April 2020